A synthesized series of PACMA (propynoic acid carbamoyl methyl amides) compounds demonstrated anticancer activity in human ovarian cancer in vitro and in vivo by a mechanism involving inhibition of PDI (Xu et al., 2012). This evidence concerns the gene PDIA2 and ovarian carcinoma.